Investigational New Drugs

, Volume 24, Issue 1, pp 85–88

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

  • Jacqueline Vuky
  • Christina Isacson
  • Mehran Fotoohi
  • Jason dela Cruz
  • Henry Otero
  • Vincent Picozzi
  • Thomas Malpass
  • David Aboulafia
  • Andrew Jacobs
Article

DOI: 10.1007/s10637-005-4543-z

Cite this article as:
Vuky, J., Isacson, C., Fotoohi, M. et al. Invest New Drugs (2006) 24: 85. doi:10.1007/s10637-005-4543-z

Summary

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with imatinib. Eligible patients had histologically confirmed RCC, metastatic and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST), Karnofsky performance status (KPS) of at least 70%, life expectancy of more than 3 months, and adequate hematological, renal, and liver function. Imatinib was given orally at a dose of 400 mg bid. The most common toxicities were Grade II/III nausea (28%) and Grade II renal insufficiency (14%). All patients had tumor tested by immunohistochemistry (IHC) for KIT protein (CD117, DAKO). One tumor (7%) demonstrated strong, diffuse expression and the rest were negative. No complete or partial responses were observed in 12 evaluable patients treated with imatinib.

Keywords

imatinib (Gleevec®) metastatic renal cell carcinoma Phase II trial 

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • Jacqueline Vuky
    • 1
    • 4
  • Christina Isacson
    • 2
  • Mehran Fotoohi
    • 3
  • Jason dela Cruz
    • 4
  • Henry Otero
    • 4
  • Vincent Picozzi
    • 4
  • Thomas Malpass
    • 1
  • David Aboulafia
    • 1
  • Andrew Jacobs
    • 1
  1. 1.Section of Hematology/Oncology, Virginia Mason Hospital and Department of MedicineUniversity of WashingtonSeattle
  2. 2.Section of Pathology, Virginia Mason Medical Center and Department of Obstetrics and GynecologyUniversity of WashingtonSeattle
  3. 3.Section of RadiologySeattle
  4. 4.Section of Hematology/OncologyVirginia Mason HospitalSeattle